Literature DB >> 21806669

Platelet activation, oxidative stress and overexpression of inducible nitric oxide synthase in moderate heart failure.

Luisa R de Meirelles1, Angela de C Resende, Cristiane Matsuura, Angelo Salgado, Natalia R Pereira, Pedro G Cascarelli, Antônio C Mendes-Ribeiro, Tatiana M C Brunini.   

Abstract

1. Chronic heart failure (CHF) is a common disabling disorder associated with thromboembolic events, the genesis of which is not yet fully understood. Nitric oxide (NO), derived from the vascular endothelium and platelets, has an important role in the physiological regulation of blood flow. It is generated from the amino acid L-arginine via NO synthase (NOS). 2. The main objective of the present study was to investigate NO production and its relationship with platelet aggregation, oxidative stress, inflammation and related amino acids in patients with moderate CHF. The expression and activity of NOS isoforms were analysed by western blotting and conversion of L-[(3)H]-arginine to L-[(3)H]-citrulline, respectively, in CHF patients (n = 12) and healthy controls (n = 15). Collagen- and ADP-induced platelet aggregation, oxidative stress (thiobarbituric acid-reactive substances (TBARS) formation and superoxide dismutase (SOD) activity) and plasma levels of amino acids and inflammatory markers (fibrinogen and C-reactive protein (CRP)) were also determined. 3. Both collagen- and ADP-induced platelet aggregation were increased in CHF patients compared with controls. Platelets from CHF patients did not show any changes in NOS activity in the presence of overexpression of inducible NOS. Systemic and intraplatelet TBARS production was elevated, whereas SOD activity was decreased in CHF patients. l-arginine plasma concentrations were lower in CHF patients than in controls. Systemic levels of CRP and fibrinogen were increased in CHF patients. 4. The results show that, in patients with moderate CHF, there is platelet activation and reduced intraplatelet NO bioavailability due to oxidative stress, which suggests a role for platelets in the prothrombotic state.
© 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21806669     DOI: 10.1111/j.1440-1681.2011.05580.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

1.  Platelet aggregometry cannot identify uremic platelet dysfunction in heart failure patients prior to cardiac surgery.

Authors:  Josh Showalter; Nghia D Nguyen; Samer Baba; Chi Hyun Lee; Jing Ning; Kimberly Klein; M Amer Wahed; Ashok Tholpady
Journal:  J Clin Lab Anal       Date:  2016-10-31       Impact factor: 2.352

2.  Diminished nitric oxide generation from neutrophils suppresses platelet activation in chronic renal failure.

Authors:  Daniele C Abrantes; Tatiana M C Brunini; Cristiane Matsuura; Wanda Vianna Mury; Carolina R Corrêa; Sérgio F Santos; Monique B O Ormonde do Carmo; Antônio Cláudio Mendes-Ribeiro
Journal:  Mol Cell Biochem       Date:  2014-12-19       Impact factor: 3.396

3.  Uncoupled eNOS annihilates neuregulin-1β-induced cardioprotection: a novel mechanism in pharmacological postconditioning in myocardial infarction.

Authors:  Bernd Ebner; Stefan A Lange; Thomas Eckert; Clementine Wischniowski; Annette Ebner; Rüdiger C Braun-Dullaeus; Christof Weinbrenner; Carsten Wunderlich; Gregor Simonis; Ruth H Strasser
Journal:  Mol Cell Biochem       Date:  2012-10-12       Impact factor: 3.396

4.  Oxidative stress: Predictive marker for coronary artery disease.

Authors:  Teodora Vichova; Zuzana Motovska
Journal:  Exp Clin Cardiol       Date:  2013

5.  The nitric oxide donor pentaerythritol tetranitrate reduces platelet activation in congestive heart failure.

Authors:  Ulrike Flierl; Daniela Fraccarollo; Julian D Widder; Jan Micka; Jonas Neuser; Johann Bauersachs; Andreas Schäfer
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

Review 6.  Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities.

Authors:  Nardev Ramanathan; Esther Tan; Li Jun Loh; Boon Seng Soh; Wei Ney Yap
Journal:  Nutr Metab (Lond)       Date:  2018-01-19       Impact factor: 4.169

7.  Ginkgo biloba Extract Reduces Hippocampus Inflammatory Responses, Improves Cardiac Functions And Depressive Behaviors In A Heart Failure Mouse Model.

Authors:  Lijun Zhang; Jianyang Liu; Yingbin Ge; Meiyan Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-29       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.